News

The European Society for Paediatric Endocrinology (ESPE) has released a position statement to encourage further research into endocrine immune-related adverse events associated with the use of immune checkpoint inhibitors in children with cancer.

For teenage boys with idiopathic short stature (ISS), combining a third-generation aromatase inhibitor with recombinant human growth hormone therapy can significantly improve adult height, suggest study findings published in the Journal of Clinical Endocrinology & Metabolism.

Study findings demonstrate the broad heterogeneous phenotypes found in children with 46,XY gonadal dysgenesis, with insights into likelihood of spontaneous puberty and risk of gonadal malignancy.

Measuring levels of testosterone, inhibin B and anti-Müllerian hormone at different time points over the first year of life may help diagnose congenital hypogonadotropic hypogonadism in infant boys with minor abnormalities of the external genitalia, French researchers say.

More than a quarter of childhood cancer survivors have moderate or severe bone mineral density deficits in adulthood, report US researchers who believe targeted interventions could reduce this burden.

Children and young adults with congenital adrenal hyperplasia may be at long-term risk of low bone mineral density, with the greatest risk found in boys and young men, Italian researchers have found.

Some children with congenital adrenal hyperplasia (CAH) could benefit from treatment with the aromatase inhibitor anastrozole to optimise their growth potential, US researchers suggest.

Once daily oral treatment with infigratinib has a tolerable side effect profile and a significant positive benefit on both annualised height velocity and upper-to-lower body segment ratio in children with achondroplasia, indicates research published in The New England Journal of Medicine.

A study of infant girls has characterised the hormonal changes of minipuberty and uncovered how the ovaries, uterus and reproductive hormones interrelate during this period.

Researchers have identified novel pathogenic variants that may account for approximately 9% of children with Silver–Russell syndrome who have not previously had a molecular diagnosis and aid understanding of the relationships between genotype and phenotype.

Use of the glucagon-like peptide -1 receptor agonist liraglutide alongside diet and exercise guidance significantly reduces BMI in children aged 6 to 11 years with severe obesity compared with lifestyle interventions alone, shows the SCALE Kids Trial.

One-year findings from the REAL5 trial show a continued growth response with use of long-acting human growth hormone treatment with somapacitan at a dose of 0.24 mg/kg per week in children born small for gestational age.